Alasdair Henderson

2.1k total citations · 1 hit paper
42 papers, 332 citations indexed

About

Alasdair Henderson is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Dermatology. According to data from OpenAlex, Alasdair Henderson has authored 42 papers receiving a total of 332 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Cardiology and Cardiovascular Medicine, 11 papers in Endocrinology, Diabetes and Metabolism and 6 papers in Dermatology. Recurrent topics in Alasdair Henderson's work include Heart Failure Treatment and Management (16 papers), Hormonal Regulation and Hypertension (9 papers) and Cardiovascular Function and Risk Factors (8 papers). Alasdair Henderson is often cited by papers focused on Heart Failure Treatment and Management (16 papers), Hormonal Regulation and Hypertension (9 papers) and Cardiovascular Function and Risk Factors (8 papers). Alasdair Henderson collaborates with scholars based in United Kingdom, United States and France. Alasdair Henderson's co-authors include Muthiah Vaduganathan, John J.V. McMurray, Pardeep S. Jhund, Brian Claggett, Faı̈ez Zannad, Carolyn S.P. Lam, Mike Kama, Van‐Mai Cao‐Lormeau, Colleen L. Lau and Bertram Pitt and has published in prestigious journals such as The Lancet, Circulation and Nature Communications.

In The Last Decade

Alasdair Henderson

31 papers receiving 324 citations

Hit Papers

Mineralocorticoid receptor antagonists in heart failure: ... 2024 2026 2025 2024 10 20 30 40 50
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis
    2024 52 citations Pardeep S. Jhund, Atefeh Talebi et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alasdair Henderson United Kingdom 10 104 83 64 54 43 42 332
Sharon Remmelzwaal Netherlands 13 119 1.1× 43 0.5× 27 0.4× 44 0.8× 39 0.9× 37 459
Pei Chia Eng United Kingdom 12 28 0.3× 203 2.4× 74 1.2× 103 1.9× 16 0.4× 41 491
Florent Guelfucci France 11 30 0.3× 100 1.2× 27 0.4× 46 0.9× 33 0.8× 23 566
Ladislav Štěpánek Czechia 10 28 0.3× 80 1.0× 32 0.5× 48 0.9× 21 0.5× 34 303
Camilo Castañeda‐Cardona Colombia 11 20 0.2× 44 0.5× 71 1.1× 29 0.5× 16 0.4× 45 320
Chang-Jin Choi South Korea 11 41 0.4× 40 0.5× 76 1.2× 17 0.3× 34 0.8× 36 332
Ayşe Kafkaslı Türkiye 16 53 0.5× 47 0.6× 130 2.0× 10 0.2× 29 0.7× 40 521
Pieralessandro Lasalvia Colombia 10 22 0.2× 54 0.7× 37 0.6× 12 0.2× 64 1.5× 52 336
B Bellemin France 6 30 0.3× 78 0.9× 193 3.0× 29 0.5× 31 0.7× 9 369
Sara J. Cromer United States 10 25 0.2× 97 1.2× 77 1.2× 107 2.0× 22 0.5× 33 351

Countries citing papers authored by Alasdair Henderson

Since Specialization
Citations

This map shows the geographic impact of Alasdair Henderson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alasdair Henderson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alasdair Henderson more than expected).

Fields of papers citing papers by Alasdair Henderson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alasdair Henderson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alasdair Henderson. The network helps show where Alasdair Henderson may publish in the future.

Co-authorship network of co-authors of Alasdair Henderson

This figure shows the co-authorship network connecting the top 25 collaborators of Alasdair Henderson. A scholar is included among the top collaborators of Alasdair Henderson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alasdair Henderson. Alasdair Henderson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Docherty, Kieran F., Antoni Bayés‐Genís, Ross T. Campbell, et al.. (2025). Benefit of early initiation of disease-modifying therapy in community-based patients with suspected heart failure. European Heart Journal. 47(8). 927–938. 1 indexed citations
2.
Henderson, Alasdair, Inder S. Anand, Akshay S. Desai, et al.. (2025). Sacubitril/valsartan and quality of life assessed using the EuroQol Five-dimension Three-level questionnaire level sum score (EQ-5D-3L-LSS) in patients with HFrEF and HFmrEF/HFpEF. European Heart Journal - Cardiovascular Pharmacotherapy. 11(7). 574–589.
3.
Butt, Jawad H., Pardeep S. Jhund, Alasdair Henderson, et al.. (2025). Finerenone, Glycaemic Status, and Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial. European Journal of Heart Failure. 27(7). 1326–1341.
4.
Chimura, Misato, Jawad H. Butt, Shingo Matsumoto, et al.. (2025). Comprehensive Analysis of the Effects of Sacubitril/Valsartan According to Sex Among Patients With Heart Failure and Reduced Ejection Fraction in PARADIGM‐HF. Journal of the American Heart Association. 14(9). e038249–e038249. 1 indexed citations
5.
Chimura, Misato, Kieran F. Docherty, Pardeep S. Jhund, et al.. (2025). Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial. European Heart Journal. 47(1). 69–79.
6.
Dobbin, Stephen J.H., Kenneth Mangion, Alasdair Henderson, et al.. (2025). Prospective Evaluation of the Cardiovascular Effects of BRAF and MEK Inhibitors in Patients With Melanoma. JACC CardioOncology. 7(7). 852–866.
7.
8.
Butt, Jawad H., Pardeep S. Jhund, Alasdair Henderson, et al.. (2025). Finerenone, Chronic Obstructive Pulmonary Disease, and Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial. European Journal of Heart Failure. 27(8). 1444–1458. 1 indexed citations
9.
Henderson, Alasdair, Joseph Hayes, Alex Lewin, et al.. (2024). Ethnic differences in depression and anxiety among adults with atopic eczema: Population‐based matched cohort studies within UK primary care. Clinical and Translational Allergy. 14(3). e12348–e12348. 1 indexed citations
10.
Jhund, Pardeep S., Atefeh Talebi, Alasdair Henderson, et al.. (2024). Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis. The Lancet. 404(10458). 1119–1131. 52 indexed citations breakdown →
11.
Henderson, Alasdair, J. Andrew McClure, Balaji Venugopal, et al.. (2024). Arterial effects of anthracycline: structural and inflammatory assessments in non-human primates and lymphoma patients. Clinical Science. 139(1). 29–41.
12.
Kondo, Toru, Alasdair Henderson, Kieran F. Docherty, et al.. (2024). Why Have We Not Been Able to Demonstrate Reduced Mortality in Patients With HFmrEF/HFpEF?. Journal of the American College of Cardiology. 84(22). 2233–2240. 7 indexed citations
13.
Causland, Finnian R. Mc, Muthiah Vaduganathan, Brian Claggett, et al.. (2024). Finerenone and Kidney Outcomes in Patients With Heart Failure. Journal of the American College of Cardiology. 85(2). 159–168. 21 indexed citations
14.
Mulick, Amy, Nick Dand, Daniel Major‐Smith, et al.. (2024). Disagreement concerning atopic dermatitis subtypes between an English prospective cohort (ALSPAC) and linked electronic health records. Clinical and Experimental Dermatology. 49(12). 1537–1546. 1 indexed citations
15.
Vaduganathan, Muthiah, Brian Claggett, Ian J. Kulac, et al.. (2024). Effects of the Nonsteroidal MRA Finerenone With and Without Concomitant SGLT2 Inhibitor Use in Heart Failure. Circulation. 151(2). 149–158. 25 indexed citations
16.
Henderson, Alasdair, Ketaki Bhate, Joseph Hayes, et al.. (2023). Severe Mental Illness Among Adults with Atopic Eczema or Psoriasis: Population-Based Matched Cohort Studies within UK Primary Care. Clinical Epidemiology. Volume 15. 363–374. 5 indexed citations
17.
Mansfield, Kathryn E., Joseph Hayes, Catherine Smith, et al.. (2023). Anxiety and Depression in People with Eczema or Psoriasis: A Comparison of Associations in UK Biobank and Linked Primary Care Data. Clinical Epidemiology. Volume 15. 891–899. 4 indexed citations
18.
Bechman, Katie, Joseph Hayes, Alasdair Henderson, et al.. (2023). Electronic screening for mental illness in patients with psoriasis. British Journal of Dermatology. 189(2). 246–248. 5 indexed citations
19.
Schonmann, Yochai, Joseph Hayes, Alasdair Henderson, et al.. (2022). Factors associated with depression, anxiety and severe mental illness among adults with atopic eczema or psoriasis: a systematic review and meta-analysis. British Journal of Dermatology. 188(4). 460–470. 21 indexed citations
20.
Henderson, Alasdair, Maïté Aubry, Mike Kama, et al.. (2020). Zika seroprevalence declines and neutralizing antibodies wane in adults following outbreaks in French Polynesia and Fiji. eLife. 9. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sharon Remmelzwaal Breakdown of academic impact, for papers by Pei Chia Eng Breakdown of academic impact, for papers by Florent Guelfucci Breakdown of academic impact, for papers by Ladislav Štěpánek Breakdown of academic impact, for papers by Camilo Castañeda‐Cardona Breakdown of academic impact, for papers by Chang-Jin Choi Breakdown of academic impact, for papers by Ayşe Kafkaslı Breakdown of academic impact, for papers by Pieralessandro Lasalvia Breakdown of academic impact, for papers by B Bellemin Breakdown of academic impact, for papers by Sara J. Cromer
Rankless by CCL
2026